Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

CRISPR–Cas12a has a low tolerance for base ... protein’s structure to further hone specificity and achieve safer in vivo-editing potential. The company studied enzyme specificity in ...

NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

基因编辑疗法具有精确性、可逆性和多样性等特点，作为一种革命性的治疗手段，基因编辑疗法正在不断推动生物医学领域的发展，为许多传统治疗方法难以解决的疾病提供了新的希望和可能性，在遗传性疾病治疗、癌症治疗、传染性疾病防治、再生医学和农业改良等方面均有应用。

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two blood ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio reorganization. Intellia is a clinical-stage gene editing company focused on ...

Several companies are using CRISPR to edit human genomes in an attempt to treat (and even cure) genetic diseases. Their therapies either use an ex vivo approach or an in vivo approach. With ex ...

(NASDAQ:EDIT), a gene editing company currently valued at approximately $157 million, has announced a strategic shift to prioritize its in vivo CRISPR gene editing programs, following recent pre ...

This expansion into autoimmune conditions represents a significant opportunity for CRISPR Therapeutics to broaden its therapeutic reach. In the realm of in vivo gene editing, CRISPR Therapeutics ...